SCHEMBL7581409

SCHEMBL7581409

CC(=O)O[C@@H](C)C(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)O)c1I

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
KLK7 P49862 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
TSHR P16473 3/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7581413 1.00 LMNA (0.42) LMNASMN1; SMN2KLK7HDAC3HDAC4
Hydrochloric Acid SCHEMBL7071547 0.98 LMNA (0.41) LMNASMN1; SMN2KLK7HDAC3HDAC4
Hydrochloric Acid SCHEMBL7581432 0.98 LMNA (0.41) LMNASMN1; SMN2KLK7HDAC3HDAC4
SCHEMBL15760479 0.96 LMNA (0.40) LMNASMN1; SMN2KLK7HDAC3HDAC4
SCHEMBL17066747 0.91 LMNA (0.36) LMNASMN1; SMN2KLK7HDAC3HDAC4
SCHEMBL14181569 0.89 LMNA (0.41) LMNAKLK7HDAC3HDAC4HDAC1
SCHEMBL5356462 0.86 LMNA (0.40) LMNAKLK7TSHR
SCHEMBL8586708 0.86 LMNA (0.43) LMNASMN1; SMN2KLK7HDAC3HDAC4
SCHEMBL6879887 0.86 LMNA (0.40) LMNAKLK7TSHR
SCHEMBL5482338 0.86 LMNA (0.40) LMNAKLK7TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723709-B1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INT LTD (CH) 2015-09-09 EP claimed
US-8835672-B2 Manufacture of a triiodinated contrast agent HOVIONE INTER LIMITED (CH) 2014-09-16 US claimed
US-20140155648-A1 Manufacture of a Triiodinated Contrast Agent HOVIONE INTER LIMITED (CH) 2014-06-05 US claimed
EP-2723709-A1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT Hovione Inter Ltd. (CH) 2014-04-30 EP claimed
WO-2012175903-A1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INTER. LTD (CH) 2012-12-27 WO claimed
EP-3580199-B1 METHOD FOR THE ONE-POT PRODUCTION OF ORGANO-IODINATED COMPOUNDS GUERBET SA (FR) 2023-04-05 EP disclosed
US-10836711-B2 Method for the one-pot production of organo-iodinated compounds GUERBET (FR) 2020-11-17 US disclosed
CN-107445858-A The production of triiodide contrast agent 霍维奥恩联合有限公司 2017-12-08 CN disclosed
EP-2723709-B1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INT LTD (CH) 2015-09-09 EP disclosed
EP-2723709-B1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INT LTD (CH) 2015-09-09 EP disclosed
US-8835672-B2 Manufacture of a triiodinated contrast agent HOVIONE INTER LIMITED (CH) 2014-09-16 US disclosed
US-8835672-B2 Manufacture of a triiodinated contrast agent HOVIONE INTER LIMITED (CH) 2014-09-16 US disclosed
EP-2723709-A1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT Hovione Inter Ltd. (CH) 2014-04-30 EP disclosed
EP-2723709-A1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT Hovione Inter Ltd. (CH) 2014-04-30 EP disclosed
WO-2012175903-A1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INTER. LTD (CH) 2012-12-27 WO disclosed
WO-2012175903-A1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INTER. LTD (CH) 2012-12-27 WO disclosed
EP-0901460-B1 A PROCESS FOR THE PREPARATION OF 5-AMINO-2,4,6-TRIIODO-1,3-BENZENEDICARBOXYLIC ACID DERIVATIVES BRACCO IMAGING SPA (IT) 2002-09-18 EP disclosed
EP-0773925-A1 PROCESS FOR THE PREPARATION OF A DICARBOXYLIC ACID DICHLORIDE Fructamine S.P.A. (IT) 1997-05-21 EP disclosed
WO-1996037460-A1 PROCESS FOR THE PREPARATION OF A DICARBOXYLIC ACID DICHLORIDE FRUCTAMINE S.P.A. (IT) 1996-11-28 WO disclosed
US-4364921-A RADIOPACITY SCHERING, AKTIENGESELLSCHAFT (DE) 1982-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836711-B2 Method for the one-pot production of organo-iodinated compounds TPO, NISCH, PPIP5K2 LMNA 3525/4885SMN1; SMN2 4729/4885KLK7 601/4885
US-20140155648-A1 Manufacture of a Triiodinated Contrast Agent SAT1, LYPLA2, AGPAT5 LMNA 2871/4885SMN1; SMN2 4778/4885KLK7 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.